An exclusive interview with Michael Graham, MD, PhD, covering the latest developments in PET radiopharmaceuticals, from drugs just approved and blazing trail in clinical use, to compounds in the far reaches of research.

Continued shutdowns at research reactors throughout the world have created shortfalls in essential medical isotope supply for several years. 

The drive for heterogeneity in molecular imaging calls for management of complex imaging data in massive volumes, a task that is challenging information technology experts and medical community members alike. 

Molecular imaging has become increasingly important in the non-invasive diagnosis and monitoring of pediatric disease, whether known or suspected. Innovations in molecular oncology, neuroimaging and hybrid imaging are shaping how clinicians approach a range of diseases in children and young adults.

Shakespeare called King Richard III a hunchback, but new genetic and reconstructive CT data show this story had more of a twist. Until recently, the exact nature and whereabouts of Richard's physical deformity was a mystery. While questions still daunt researchers, a compelling picture of the monarch's spine has emerged.

The use of PET radiopharmaceuticals increased from 17 percent to 26 percent in diagnostic nuclear medicine procedures, according to a report evaluating adverse effects published May 29 in the Journal of Nuclear Medicine.

In a comparison safety study between scintigraphy and 256-slice angiography for pregnant women suspected of having a pulmonary embolism, scintigraphy was found to be the safest choice for moms and their unborn babies, according to a study published May 29 in the Journal of Nuclear Medicine.

The biopharmaceutical company Eli Lilly based in Indianapolis, announced yesterday that it is collaborating in the development of Qiagen’s modular assay panels that allow simultaneous study of multiple biomarkers under investigation by Lilly. This comes on the heels of news that Lilly has made a sizable investment in an $80 million Epidarex Capital fund for early-stage life science and health technology companies in the United Kingdom.